With increasing popularity of Industry Theaters, ATS 2015 will deliver more offerings than ever before. Professionals will lead a total of 19 Industry Theater and Mini Industry Theater discussions in the Exhibit Hall. Have lunch while learning about new product launches and treatment options. Complimentary boxed lunch will be provided by the ATS while supplies last.
Today
11:45 a.m. to 12:30 p.m.
Industry Theater 1
The Role of Bronchodilators in the Long-Term Maintenance Treatment of Patients with COPD: A Review of the Data
Discover the mist. A dynamic presentation of the role of bronchodilators in the long-term maintenance treatment of patients with COPD. An expert speaker will review the efficacy and safety data of bronchodilator maintenance treatments as well as the features of the inhaler.
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
1 to 1:45 p.m.
Industry Theater 1
Are We Gaining the Maximum Benefit from Bronchodilators in COPD?
(Open to non-U.S. based physicians only)
During this industry theater supported by Novartis, Chairman Ken Chapman will pose pertinent clinical questions on COPD therapies to a faculty of world-renowned experts. The program will highlight the fundamental role of bronchodilators in COPD management, and will discuss key data on indacaterol and glycopyrronium, as well as the efficacy and safety profile of the dual bronchodilation combination indacaterol/glycopyrronium. Inhaled corticosteroids (ICS) have been used in COPD management for many years but their use in practice is often contrary to guideline recommendations. New and recent evidence— demonstrating that, for many patients, effective bronchodilation may be a better option than ICS-containing regimens—will be shown. The appropriate ICS patient, data from recent ICS withdrawal trials, and use of alternative agents will be discussed.
Speakers: Chair: Professor Ken Chapman, University of Toronto, Canada; Effective Use of Bronchodilators in COPD; Professor José Jardim, Federal University of Sí£o Paulo, Brazil; Re-thinking the Use of ICS in COPD; and Professor Marc Miravitlles, Hospital Universitari Vall d’Hebron, Barcelona, Spain
Company: Novartis Pharma AG
11:45 a.m. to 12:30 p.m.
Industry Theater 2
Want to Add More to Your PAH Treatment Strategy?
Join a panel of experts for a poster-themed discussion on disease progression in pulmonary arterial hypertension, adding prostacyclin class therapy in appropriate patients, and how an inhaled prostacyclin-class therapy may help. Topics include diagnosis, clinical trial study design, efficacy, side effects, dosing, and therapy management. Lunch provided.
Speakers: Steven Nathan, MD, FCCP, Medical Director, Advanced Lung Disease and Lung Transplant Programs, Inova Fairfax Hospital, Falls Church, VA; Lynette Brown, MD, PhD, Associate Director, Pulmonary Hypertension Program, Intermountain Medical Center, Murray, UT; and Glenna Traiger, RN, MSN, CNS-BC, Pulmonary Hypertension CNS, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Company: United Therapeutics Corporation
1 to 1:45 p.m.
Industry Theater 2
The Role of Nitric Oxide (NO) in the Pathology of PAH (WHO Group 1) and CTEPH (WHO Group 4)
Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are two different forms of pulmonary hypertension, characterized by elevated pulmonary artery pressures and increased pulmonary vascular resistance. Impaired synthesis of endogenous nitric oxide contributes to the pathology of both diseases. PH experts will present and discuss a CTEPH case and a PAH case that are typical of patients who may be encountered in practice.
Speakers: Nicholas S. Hill, MD, Professor of Medicine, Chief, Pulmonary, Critical Care and Sleep Division, Tufts University School of Medicine, Boston, MA, and Nick H. Kim, MD, Clinical Professor of Medicine, Director, Pulmonary Vascular Medicine, University of California San Diego School of Medicine San Diego, CA
Company: Bayer HealthCare Pharmaceuticals
11:30 a.m. to Noon
Mini Industry Theater
Pattern Recognition and Identification of Idiopathic Pulmonary Fibrosis (IPF)
Come explore a hands-on learning adventure, presented by thought-leader experts on IPF. This program features a uniquely designed, high-impact visual exploration of IPF. Participants will also be invited to test their new knowledge via polling questions interspersed throughout the program.
Company: Genentech, Inc.
12:30 to 1 p.m.
Mini Industry Theater
Pattern Recognition and Identification of Idiopathic Pulmonary Fibrosis (IPF)
Come explore a hands-on learning adventure, presented by thought-leader experts on IPF. This program features a uniquely designed, high-impact visual exploration of IPF. Participants will also be invited to test their new knowledge via polling questions interspersed throughout the program.
Company: Genentech, Inc.
1:30 to 2 p.m.
Mini Industry Theater
Pattern Recognition and Identification of Idiopathic Pulmonary Fibrosis (IPF)
Come explore a hands-on learning adventure, presented by thought-leader experts on IPF. This program features a uniquely designed, high-impact visual exploration of IPF. Participants will also be invited to test their new knowledge via polling questions interspersed throughout the program.
Company: Genentech, Inc.